CTOs on the Move

Curve Biosciences

www.curvebio.com

 
Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curvebio.com
  • 319 North Bernardo Avenue
    Mountain View, CA USA 94043
  • Phone: n/a

Executives

Name Title Contact Details
Nathan Hunkapiller
 Chief Technology Officer Profile

Similar Companies

Zymo Research Corporation

Zymo Research Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SyntheZyme

SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how

Michael

Michael is a Franklinton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corium International

Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.